Examining the reasons, it is apparent that developing and manufacturing a new drug requires substantial investment. There is no assurance of success during the human trials phase. In addition, because Taiwan's drug companies are small, they are much less willing to risk large investments than are big multinational pharmaceutical firms.
究其原因，研發製造新藥需要相當大的投資，在人體實驗階段，誰都沒有把握一定會成功，而台灣的製藥公司規模都很小，冒險大舉投資的勇氣當然比不上國際大藥廠。